MAIA•benzinga•
MAIA Biotechnology Reports Updated Phase 2 THIO-101 Trial Data Showing Median Overall Survival Of 17.8 Months With Ateganosine Plus Cemiplimab In Heavily Pre-Treated NSCLC Patients
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 5, 2025 by benzinga